BioAdvance

About The Fund

BioAdvance is a venture capital firm founded in 2002, focusing on investments in the diagnostics, life sciences, healthcare, information technology, and research tool sectors. Operating from Philadelphia, Pennsylvania, with an additional office in Radnor, Pennsylvania, BioAdvance has carved out a niche in seed, early-stage, and later-stage investments, particularly within companies based in the Mid-Atlantic region. They are committed to enhancing human health and well-being by backing innovative companies in the biotech, hardware, health tech and fitness, medical devices, investment management, life science, and pharmaceutical sectors. BioAdvance operates as an evergreen fund, meaning they reinvest returns from their investments to support sustainable, long-term growth and maintain a long-term investment perspective. Their investment strategy is not just about providing capital but also about creating value and growth for their portfolio companies. These companies, part of their varied portfolio, have collectively attracted over $4.2 billion of external capital to support their expansion. With investment minimums of $1,500,000, maximums of $5,000,000, and a 'sweet spot' at around $3,300,000, BioAdvance is positioned to support early, seed, later, Series A, and Series B funding rounds. They also engage in pre-seed investments. This strategic focus on investing in life-science companies in the Mid-Atlantic region underscores their goal to launch successful companies that contribute meaningful advancements in healthcare.